Literature DB >> 15205467

Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity.

Galit Elad-Sfadia1, Roni Haklai, Eyal Balan, Yoel Kloog.   

Abstract

Depending on the cellular context, Ras can activate characteristic effectors by mechanisms still poorly understood. Promotion by galectin-1 of Ras activation of Raf-1 but not of phosphoinositide 3-kinase (PI3-K) is one such mechanism. In this report, we describe a mechanism controlling selectivity of K-Ras4B (K-Ras), the most important Ras oncoprotein. We show that galectin-3 acts as a selective binding partner of activated K-Ras. Galectin-3 co-immunoprecipitated significantly better with K-Ras-GTP than with K-Ras-GDP, H-Ras, or N-Ras and colocalized with green fluorescent protein-K-Ras(G12V), not with green fluorescent protein-H-Ras(G12V), in the cell membrane. Co-transfectants of K-Ras/galectin-3, but not of H-Ras/galectin-3, exhibited enhanced and prolonged epidermal growth factor-stimulated increases in Ras-GTP, Raf-1 activity, and PI3-K activity. Extracellular signal-regulated kinase (ERK) activity, however, was attenuated in K-Ras/galectin-3 and in K-Ras(G12V)/galectin-3 co-transfectants. Galectin-3 antisense RNA inhibited the epidermal growth factor-stimulated increase in K-Ras-GTP but enhanced ERK activation and augmented K-Ras(G12V) transformation activity. Thus, unlike galectin-1, which prolongs Ras activation of ERK and inhibits PI3-K, K-Ras-GTP/galectin-3 interactions promote, in addition to PI3-K and Raf-1 activation, a third inhibitory signal that attenuates active ERK. These experiments established a novel and specific mechanism controlling the duration and selectivity of signals of active K-Ras, which is extremely important in many human tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205467     DOI: 10.1074/jbc.M312697200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  110 in total

1.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.

Authors:  Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

2.  Mathematical modeling of K-Ras nanocluster formation on the plasma membrane.

Authors:  Tianhai Tian; Sarah J Plowman; Robert G Parton; Yoel Kloog; John F Hancock
Journal:  Biophys J       Date:  2010-07-21       Impact factor: 4.033

Review 3.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

Review 4.  Ras plasma membrane signalling platforms.

Authors:  John F Hancock; Robert G Parton
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

5.  Identifying optimal lipid raft characteristics required to promote nanoscale protein-protein interactions on the plasma membrane.

Authors:  Dan V Nicolau; Kevin Burrage; Robert G Parton; John F Hancock
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 6.  Ras nanoclusters: molecular structure and assembly.

Authors:  Daniel Abankwa; Alemayehu A Gorfe; John F Hancock
Journal:  Semin Cell Dev Biol       Date:  2007-08-19       Impact factor: 7.727

Review 7.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

8.  Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.

Authors:  Byron J Aguilar; Augustine T Nkembo; Randolph Duverna; Rosemary A Poku; Felix Amissah; Seth Y Ablordeppey; Nazarius S Lamango
Journal:  Eur J Med Chem       Date:  2014-05-09       Impact factor: 6.514

9.  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

Authors:  Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

10.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.